Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream in plaque psoriasis (2-20% BSA)
NCT00617994Phase 2Completed
- Sponsor
- Incyte
- Start
- Aug 2007
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib cream in plaque psoriasis (3 arms), sponsored by Incyte. Primary endpoints: Treatment Emergent Adverse Events at 3 months, Skin Flux of INCB018424 at 30 days and 2 more. Started Aug 2007; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00617994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617994.